Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1α level.
Department of Diabetes and Metabolism Internal Medicine, Kobari General Hospital, 29-1, Yokouchi, Noda city, Chiba 278-8501, Japan.
Tatsuhiko
T
Saito
Kei
K
Ohnuma
Hiroshi
H
Suzuki
Nam H
NH
Dang
Ryou
R
Hatano
Hiroki
H
Ninomiya
Chikao
C
Morimoto
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001168:Arthritis / Q000139:chemically induced*; D054377:Chemokine CXCL12 / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000009:adverse effects*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects*
C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate
CD26; DPP-4; DPP-4 inhibitors; Polyarthropathy; SDF-1α